Allergan Reports Strong Second Quarter 2016 Continuing Operations Performance with Net Revenues of $3.7 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Remains Sidelined on Allergan (AGN) Following Mixed 2Q
August 9, 2016 9:08 AM EDTPiper Jaffray maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $227.00 (from $236.00), following the company's 2Q earnings report. AGN reported non-GAAP diluted EPS of $3.35 on revenue of $3.68B, compared to Street estimates of $3.33 and $3.97B, respectively.
Analyst David Amsellem commented, "Allergan... More
Allergan (AGN) CEO Says Not Focused on or Looking at Large Deals (BIIB)
August 8, 2016 9:21 AM EDTAllergan's (NYSE: AGN) CEO said the company isn't focused on or looking at large deals.
Traders are watching shares of rumored target Biogen (NASDAQ: BIIB) following the comments.
... MoreAllergan (AGN) Tops Q2 EPS by 1c
August 8, 2016 7:02 AM EDTAllergan (NYSE: AGN) reported Q2 EPS of $3.35, $0.01 better than the analyst estimate of $3.34. Revenue for the quarter came in at $3.68 billion versus the consensus estimate of $4.1 billion.
For earnings history and earnings-related data on Allergan (AGN) click here.
... More